ArticleJAMA2009
Major lipids, apolipoproteins, and risk of vascular disease.
Article in JAMA, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,125 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Differential Effects of Total Cholesterol, Non-HDL Cholesterol and Triglycerides on Initial Presentation of Specific Cardiovascular Diseases (a CALIBER Study)
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
Who cites it
1,125 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,738 citations in OpenAlex.
- A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.PharmacoEconomics · 2026Pooled it
- Effects and Dose-Response Relationship of High-Intensity Interval Training on Cardiometabolic Risk in Individuals With Overweight and Obesity: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Comparison of the health-related outcomes for traditional cigarettes, e-cigarettes, heat-not-burn cigarettes and snus: a systematic review and meta-analysis.BMC public health · 2026Pooled it
- Causal association between lipoproteins and risk of coronary artery disease-a systematic review and meta-analysis of Mendelian randomization studies.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- Short-term glycemic variability and the risk of adverse ICU outcomes in critically ill patients: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Trial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Low-Density Lipoprotein Cholesterol Reductions of not Less Than 60 mg/dL Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Lipid-lowering effect of combined therapy with high-intensity statins and CETP inhibitors: a Systematic Review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Efficacy and safety of Chinese herbal medicine for metabolic conditions: a systematic review and meta-analysis of randomised controlled trials.Frontiers in pharmacology · 2025Pooled it
- Trial
- Machine Learning-Based Prediction of Comprehensive Lipid Response to Dietary Interventions in Overweight and Obese Women.Nutrients · 2026Trial
- Article
- Interpreting Lower HDL Cholesterol in Plant-Based Diets: Mechanisms and Clinical Implications.Advances in nutrition (Bethesda, Md.) · 2026Review
- Multi-omic characterization of the Hispanic/Latino blood lipidome reveals an additional locus and attenuated genetic prediction.HGG advances · 2026Article
- Clinical-Metabolic Risk Phenotypes and Carotid Plaque Burden Among Community-Dwelling Individuals at High Cardiovascular Risk: An Exploratory Cross-Sectional Study.Journal of cardiovascular development and disease · 2026Article
- HDL Cholesterol and the Triglyceride-to-HDL Cholesterol Ratio in Relation to Coronary Artery Disease Complexity in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Estimating genetic correlation jointly using individual-level and summary-level GWAS data.Nature communications · 2026Article
- The role of genetic variation in apolipoprotein response to diet among Brazilians with cardiovascular disease.European journal of clinical nutrition · 2026Article
- Machine Learning Reveals the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population.Circulation. Genomic and precision medicine · 2026Article
- Article
1,065 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
contextAssociations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.
objectiveTo assess major lipids and apolipoproteins in vascular risk. DESIGN, SETTING, AND
participantsIndividual records were supplied on 302,430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.
main outcome measuresHazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis.
resultsThe rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.
conclusionLipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.